For years, clinicians treating chronic insomnia have faced a common question from patients: should I take a sleeping pill, do therapy, or both? The American Academy of Sleep Medicine (AASM) has now provided its first direct answer, publishing a clinical practice guideline in the Journal of Clinical Sleep Medicine that explicitly addresses when and how to combine cognitive behavioral therapy for insomnia (CBT-I) with medication.
The bottom line is asymmetric — and telling. The AASM recommends combination therapy over medication alone, but does not recommend it over CBT-I alone. In practical terms: if a patient is currently taking sleeping pills without therapy, adding CBT-I improves outcomes. But if a patient is already doing CBT-I, adding medication does not offer a clear benefit.
Two Conditional Recommendations
The guideline issues two specific recommendations, both classified as "conditional" with low certainty of evidence:
Recommendation 1: The AASM suggests the use of combination treatment (CBT-I plus insomnia medication) over insomnia medication alone.
Recommendation 2: The AASM suggests against the use of combination treatment over CBT-I alone.
The "conditional" designation means clinicians should weigh individual patient preferences and circumstances rather than applying the recommendations universally. But the directional message is clear: CBT-I remains the indispensable component of insomnia treatment, while medication is a useful adjunct under specific circumstances.
When Combination Therapy Makes Sense
The guideline identifies a specific patient profile that may benefit from combination treatment over CBT-I alone: those who place higher value on increasing total sleep time early in the course of treatment, and who place lower value on reducing daytime symptoms. In other words, patients who need faster results in terms of raw hours of sleep — even if that comes at the cost of some daytime benefits — may reasonably choose the combined approach.
This distinction matters because CBT-I typically takes two to eight weeks to produce its full effects, during which patients may experience temporary worsening of sleep as they implement techniques like sleep restriction. Adding a short-term medication can bridge that gap.
Specific Medication Recommendations
The guideline also provides the AASM's most detailed medication recommendations for insomnia to date, broken down by symptom profile:
- Sleep onset insomnia (difficulty falling asleep): triazolam, ramelteon, zaleplon
- Sleep maintenance insomnia (difficulty staying asleep): doxepin, suvorexant
- Combined sleep onset and maintenance insomnia: temazepam, zolpidem, eszopiclone
Each of these received conditional recommendations, reflecting the AASM's position that no single medication has demonstrated strong enough evidence to earn an unconditional endorsement.
Why This Guideline Matters Now
Previous AASM guidelines — published in 2017 for pharmacological treatments and in 2021 for behavioral treatments — evaluated each approach in isolation. Clinicians who wanted guidance on combining them had no official recommendation to reference, leaving the decision to individual judgment and often resulting in wide variation in practice.
The new guideline, accompanied by a systematic review and meta-analysis published in the same issue of JCSM, represents the first time the AASM has directly compared combined treatment against each monotherapy. The accompanying evidence review found meaningful improvements in some sleep outcomes with combination therapy versus medication alone, but no consistent advantage over CBT-I alone.
The Broader Trajectory
The guideline arrives at a moment when access to CBT-I remains a bottleneck. Despite being the recommended first-line treatment for chronic insomnia across multiple international guidelines, CBT-I is available to only a fraction of the estimated 30 million Americans with chronic insomnia. There are not enough trained therapists, sessions are often not covered by insurance, and wait times can stretch to months.
Digital CBT-I platforms have expanded access significantly in recent years, with several earning FDA authorization. But the new combination guideline may also shift prescribing patterns by discouraging the common practice of prescribing sleep medication without simultaneously offering or recommending behavioral therapy — a practice the evidence now explicitly does not support.
What This Means for Patients
If you are currently managing insomnia with medication alone, this guideline provides a clear signal: adding CBT-I is likely to improve your outcomes. If you are already in CBT-I and wondering whether medication would help, the answer is more nuanced — it depends on how urgently you need more sleep hours in the short term. The one clear takeaway is that medication without behavioral therapy is the least supported approach.
The guideline was published April 13, 2026, in the Journal of Clinical Sleep Medicine and is available through the AASM website.
